Alvotech And DKSH Partner On Adalimumab In Asia
After Deals In Canada, Europe And Israel, Alvotech Targets Asia
Executive Summary
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.
You may also be interested in...
Alvotech Gears Up For Public Listing With Fresh Leadership
Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.
Alvogen And Zentiva Complete CEE Deal
Alvogen’s central and eastern European business, which started up in 2010, has now been sold to the Zentiva group. Zentiva plans to combine both companies’ branded generics and OTC businesses in the CEE region.
Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: